Phase 2, Randomized, Double-Blind, Placebo-Controlled of the Efficacy and Safety of CF102 in Hepatocellular Carcinoma (HCC)

Study ID
NCT02128958

Study type
Interventional

Study phase
Phase 2

Study status
Completed

Trial Acronym

Trial Summary

This is a multicenter, randomized, double-blind, placebo-controlled clinical trial in subjects with advanced HCC and CPB cirrhosis whose disease has progressed while taking 1 prior systemic drug therapy for HCC.

More informations

Trial Starting Date

Sep 30,2014

Requirements

Gender All
Minimum age 18 Years
Maximum age N/A

Enrollement Limit